4 results
Approved WMOCompleted
The primary objective is to determine the efficacy of neo-adjuvant chemotherapy to reduce tumour size below 2 cm in diameter and thus enabling conisation.
Approved WMOCompleted
Primary* To evaluate the effect of EDP1066 in multiple formulations on the systemic immune system.Secondary* To evaluate the safety and tolerability of EDP1066 in multiple formulations.
Approved WMORecruiting
Main objective: response rate and tumour size reduction by neoadjuvant chemotherapy.
Approved WMOPending
Main objective: response rate and tumour size reduction by chemotherapy